摘要
20世纪80年代后期,有研究表明,抗菌药物喹诺酮对真核细胞的II型拓扑异构酶具有显著的抵抗作用并且对肿瘤细胞显示出有细胞毒活性。因此,一些制药公司发起的喹诺酮类药物抗癌计划,把常规的人拓扑异构酶II抑制抗肿瘤药物如阿霉素和足叶乙甙与喹诺酮类药物进行对比。在今天以主要途径为基础(而非以细胞毒性为基础)的肿瘤药物研发环境,本文对喹诺酮类抗癌潜力的进行了现代化的评估。本文与相应的核数据进行对比,并与最近的结构生物学信息融合,对喹诺酮核SAR的进行了全面讨论,生物学信息是解释SAR的基础。喹诺酮类药物拓扑异构酶II抑制剂更难外排介导抗性,这是目前统药物治疗的缺点。人类拓扑异构酶II型的生物学研究表明,人类在克服常规Topo II抑制剂治疗的缺点方面的研究将取得巨大进展,即心脏毒性和药物引起的继发性白血病。由于未来在许多癌症治疗需要有效的拓扑异构酶II型抑制剂药物,喹诺酮类Topo II抑制剂可能有着良好的治疗作用,因为其生物和结构优势第一次对优于现有药物的新型抑制剂的设计提供了指导。
关键词: 喹诺酮类药物,氟喹诺酮类药物,拓扑异构酶,DNA旋转酶,topo II, topo IV,抗肿瘤,抗癌,抗菌,细胞毒,选择性,保Paul Ehrlich
Current Medicinal Chemistry
Title:A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone
Volume: 23 Issue: 6
Author(s): Gregory S. Bisacchi and Michael R. Hale
Affiliation:
关键词: 喹诺酮类药物,氟喹诺酮类药物,拓扑异构酶,DNA旋转酶,topo II, topo IV,抗肿瘤,抗癌,抗菌,细胞毒,选择性,保Paul Ehrlich
摘要: In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today’s predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Export Options
About this article
Cite this article as:
Gregory S. Bisacchi and Michael R. Hale , A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone, Current Medicinal Chemistry 2016; 23 (6) . https://dx.doi.org/10.2174/0929867323666151223095839
DOI https://dx.doi.org/10.2174/0929867323666151223095839 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements